POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.598 EUR | -1.32% |
|
-6.42% | +8.53% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.41M | Sales 2022 | 674K 725K | Capitalization | 27.16M 29.21M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.74M | Net income 2022 | -31M -33.34M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.23M | Net Debt 2022 | 32.74M 35.21M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
More news
| 1 day | -1.98% | ||
| 1 week | -7.04% | ||
| Current month | -5.41% | ||
| 1 month | -12.78% | ||
| 3 months | +35.00% | ||
| 6 months | +69.71% | ||
| Current year | +7.80% |
1 week
0.58
0.69
1 month
0.580.69
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 0.598 | -1.32% | 132 005 |
| 24-06-07 | 0.606 | -5.31% | 172,883 |
| 24-06-06 | 0.64 | -3.32% | 100,609 |
| 24-06-05 | 0.662 | +3.60% | 431,432 |
| 24-06-04 | 0.639 | 0.00% | 79,670 |
Real-time Euronext Paris, June 10, 2024 at 08:27 am EDT
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-08-28
- Q2 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +7.80% | 31.14M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +0.73% | 22.78B | |
| -10.58% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- POXEL Stock
